Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels
The possible estrogenic effects of tamoxifen on plasma lipids and antithrombin III levels were investigated in 91 breast cancer patients. Mean values of total, HDL and LDL cholesterol, triglycerides, glucose, uric acid, and antithrombin III were evaluated in 55 patients on adjuvant tamoxifen for at least 3 months and compared with those found in 36 patients on no therapy. Total cholesterol, LDL cholesterol, and antithrombin III levels were significantly lower in treated patients (p<0.05).
Our results support the hypothesis of a partial agonist action of this antiestrogen, although general clinical practice suggests that tamoxifen-related thrombotic events are rare.
Key wordstamoxifen adjuvant endocrine therapy plasma lipids antithrombin III
Unable to display preview. Download preview PDF.
- 4.Dixon WJ: BMDP Statistical Software. University of California, Berkeley, 1981Google Scholar
- 5.Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustration of cases. Lancet 2: 102–104, 1896Google Scholar
- 6.Proceedings of the NIH Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer. NCI Monographs 1, 1986Google Scholar
- 7.Patterson JS, Battersby LA, Edwards DG: Review of the clinical pharmacology and international experience with tamoxifen in advanced breast cancer. Rev Endocrine Related Cancer, Suppl 9: 563–582, 1982Google Scholar
- 9.Jacquot C, Graterol R, Bariety J, Capron L, Fiessinger JN: DES versus tamoxifen in advanced breast cancer (Letter). N Engl J Med 304: 1042, 1981Google Scholar
- 10.Nevasaari K, Heikkinen M, Taskinen PJ: Tamoxifen and thrombosis (Letter). Lancet 2: 946–947, 1978Google Scholar